WILLIAM P. VAUGHAN, M.D.; RUTH B. PURTILO, Ph.D.; CARL D. BUTLER, B.B.A.; JAMES O. ARMITAGE, M.D.
This content is PDF only. Please click on the PDF icon to access.
Rapidly expanding interest in autologous marrow transplantation (AMT) as a supportive care technology that permits very-high-dose, curative-intent chemotherapy for malignancy has resulted in the definition of large numbers of patients as "eligible" for this form of therapy. Including only those patients with malignancies for which treatment strategies involving this technique already have shown a possibility of cure, and only patients less than 50 years of age, there may be as many as 40 000 patients per year in the United States who are candidates (1). At an average cost per patient of $100 000, the total cost to treat 40
VAUGHAN WP, PURTILO RB, BUTLER CD, et al. Ethical and Financial Issues in Autologous Marrow Transplantation: A Symposium Sponsored by the University of Nebraska Medical Center. Ann Intern Med. 1986;105:134–135. doi: https://doi.org/10.7326/0003-4819-105-1-134
Download citation file:
Published: Ann Intern Med. 1986;105(1):134-135.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use